Cytospire Therapeutics

Private

LondonHealthcare & Life Scienceshttps://www.cytospire.com/

Last Round

Series A

May 5, 2026

Total Funding Raised

$83M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Cytospire Therapeutics is a biotechnology company developing a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

gamma delta T cell engagerspan-gamma delta T cell engagersimmuno-oncologyIOT cell engagerssolid tumor therapybispecific antibodiesgamma delta T cell therapygd T cell therapymultispecific antibodiesantibody engineeringimmune cell engagersEGFR targeted therapydrug discovery platformpreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cytospire Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Cytospire Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cytospire Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	May 5, 2026

View all Funding Rounds

Key People

Founding team and executive leadership

Natalie Mount

Chief Executive Officer

Executive Team

Cytospire Therapeutics Investors

Notable investors and investment history

Cytospire Therapeutics investors
Investor	Rounds
Servier Ventures	Series A
Medical Incubator Japan	Series A
British Business Bank	Series A
4BIO Capital	Seed, Series A
Abingworth	Series A, Seed
Pathway Bioventures	Series A
LifeArc Ventures	Series A, Seed

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 27, 2026
Grew 17% QoQ, from 18 to 21 employees.
May 5, 2026
$83M round led by 4Bio Capital

View all signals

Cytospire Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Cytospire Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cytospire Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon

Employee Range21

Year Founded2023

Last FundingMay 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.